Evidence map›Paper›PMID 33723363›Full record

ArticleProstate cancer and prostatic diseases2021

Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.

Minh-Phuong Huynh-Le, Roshan Karunamuni, Chun Chieh Fan, Wesley K Thompson, Kenneth Muir, Artitaya Lophatananon, Karen Tye, Alicja Wolk, Niclas Håkansson, Ian G Mills and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Minh-Phuong Huynh-LeDivision of Radiation Oncology, George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-5025-4709
Roshan KarunamuniDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8723-8123
Chun Chieh FanCenter for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, CA, USA.
Wesley K ThompsonDivision of Biostatistics and Halicioğlu Data Science Institute, University of California San Diego, La Jolla, CA, USA.
Kenneth MuirDivision of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0001-6429-988X
Artitaya LophatananonDivision of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.
Karen TyeDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Alicja WolkUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Niclas HåkanssonUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Ole A AndreassenNORMENT, KG Jebsen Centre, Oslo University Hospital and University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-4461-3568
Anders M DaleCenter for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6126-2966
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. tseibert@ucsd.edu.ORCID http://orcid.org/0000-0002-4089-7399
PRACTICAL Consortium

Funding

Improving assessment of prostate cancer bone metastases using advanced diffusion imagingK08EB026503 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SEIBERT, TYLER MICHAEL · 2019 to 2022
$805k
NCI NIH HHS L30 CA231417NIBIB NIH HHS K08 EB026503
6 · The paper itself

Abstract

backgroundClinical variables-age, family history, genetics-are used for prostate cancer risk stratification. Recently, polygenic hazard scores (PHS46, PHS166) were validated as associated with age at prostate cancer diagnosis. While polygenic scores are associated with all prostate cancer (not specific for fatal cancers), PHS46 was also associated with age at prostate cancer death. We evaluated if adding PHS to clinical variables improves associations with prostate cancer death.

methodsGenotype/phenotype data were obtained from a nested case-control Cohort of Swedish Men (n = 3279; 2163 with prostate cancer, 278 prostate cancer deaths). PHS and clinical variables (family history, alcohol intake, smoking, heart disease, hypertension, diabetes, body mass index) were tested via univariable Cox proportional hazards models for association with age at prostate cancer death. Multivariable Cox models with/without PHS were compared with log-likelihood tests.

resultsMedian age at last follow-up/prostate cancer death was 78.0 (IQR: 72.3-84.1) and 81.4 (75.4-86.3) years, respectively. On univariable analysis, PHS46 (HR 3.41 [95% CI 2.78-4.17]), family history (HR 1.72 [1.46-2.03]), alcohol (HR 1.74 [1.40-2.15]), diabetes (HR 0.53 [0.37-0.75]) were each associated with prostate cancer death. On multivariable analysis, PHS46 (HR 2.45 [1.99-2.97]), family history (HR 1.73 [1.48-2.03]), alcohol (HR 1.45 [1.19-1.76]), diabetes (HR 0.62 [0.42-0.90]) all remained associated with fatal disease. Including PHS46 or PHS166 improved multivariable models for fatal prostate cancer (p < 10

conclusionsPHS had the most robust association with fatal prostate cancer in a multivariable model with common risk factors, including family history. Adding PHS to clinical variables may improve prostate cancer risk stratification strategies.

Indexed as

Genetic Predisposition to DiseaseAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesFollow-Up StudiesHumansLongitudinal StudiesMalePrognosisProstatic NeoplasmsSurvival RateSwedenBiomarkers, Tumor

Identifiers

PMID33723363
PMCPMC8387332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.